Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a dermatologist at Seattle Children's Hospital, about nuanced differences in guideline-recommended use of oral JAK inhibitors in pediatric patients with moderate-to-severe atopic dermatitis (AD): bit.ly/4e59O60

Innovent Biologics announced that picankibart (IBI112) has met all the primary endpoints and key secondary endpoints in the phase 3 registrational study (CLEAR-1) in Chinese subjects with moderate to severe plaque psoriasis. bit.ly/3yF2dLh

A recent survey conducted by Almirall showed gaps in public awareness about actinic keratosis (AK) and the associated risks of sun exposure. bit.ly/3R4bm6n

New research suggests that increased use of antihypertensive medications is associated with an increase in eczematous dermatitis. bit.ly/3Vem4tC

The US Food and Drug Administration (FDA) is doing Americans a disservice by not approving many of the modern sunscreens that are commonly used in Europe, a representative from the Environmental Working Group (EWG) told the TODAY television show last week. bit.ly/4buNP6O

New research suggests that patients with melanoma who engage in more frequent visits to the dermatologist show higher rates of survival. bit.ly/44NVESJ

A recent study highlighted growing concerns within the dermatological community regarding an increase in treatment-resistant fungal strains. bit.ly/3yoQAIl

Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. bit.ly/3UCFGG8

Modern Aesthetics Editorial Board member Jeanine B. Downie, MD, FAAD, took a big step May 13. Dr. Downie joined PIX11 Morning News in New York, explaining how neurotoxins work, which brands are FDA approved, & who should be administering them. Read Here: bit.ly/4bGKcuu

A recent survey conducted by the American Academy of Dermatology (AAD) highlighted the heightened risk of sunburn and skin cancer faced by outdoor workers in the United States. bit.ly/4dKhGtq

A recent Forbes article suggests a potential connection between dermal fillers and body dysmorphic disorder (BDD), a condition estimated by the BDD Foundation to occur in 2% of the adult population. bit.ly/3K1geFG

The acne vulgaris market reached a value of US$ 7.0 Billion in 2023 and is anticipated to grow at a CAGR of 3.23% to more than $10 billion by 2034, according to a report by the IMARC Group. bit.ly/4dzJ3q5

In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD: bit.ly/4dD6Buu

Boehringer Ingelheim anounced that it has received FDA approval for a high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm). bit.ly/4bwPKaQ

Results from a two-study analysis in the Journal of Drugs in Dermatology suggested efficacy for an over-the-counter healing ointment in improving skin hydration and wound healing outcomes following dermatologic procedures. bit.ly/3Wx6PNy

New topline results in evaluating the efficacy and safety of upadacitinib for adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable. bit.ly/3wgoGgQ

New research unveils the hidden impact on mental health that some chronic skin conditions take for pediatric patients. Read on here: bit.ly/4aVxuba

Join the competition for the inaugural KOL KNOCKOUT™ in Oculoplastics! Register here today! evolvemeded.com/webinars/2407-…

Alopecia areata (AA) is known to impact the health-related quality of life (HRQoL) of affected individuals, yet there is a paucity of research focusing on its effects specifically in pediatric patients and their families.

Read on here: bit.ly/49TlBkH